SCHEMBL3343544

SCHEMBL3343544

COC(=O)c1ccc(-c2noc(-c3cn4cc(C(F)(F)F)cc(Cl)c4n3)n2)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.48
NPC1 O15118 5/20 0.48
RAB9A P51151 5/20 0.48
NFKB1 P19838 4/20 0.48
NFKB2 Q00653 4/20 0.48
RELA Q04206 4/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
MAPT P10636 2/20 0.45
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RECQL P46063 1/20 0.44
PKM P14618 1/20 0.42
CNR2 P34972 2/20 0.40
RARA P10276 7/20 0.40
RARB P10826 7/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2495280 0.90 NPC1 (0.44) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL3342764 0.89 NPC1 (0.48) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL3341615 0.89 NPC1 (0.51) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL3342970 0.88 NPC1 (0.47) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL3339549 0.86 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL2494462 0.86 NPC1 (0.42) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL3340394 0.85 SMN1; SMN2 (0.55) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL3340947 0.85 SMN1; SMN2 (0.62) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL3343605 0.84 NPC1 (0.46) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL13330766 0.84 RARA (0.40) SMN1; SMN2NPC1RAB9ANFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
WO-2010065760-A1 IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION EXELIXIS, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 SMN1; SMN2 2046/4885NPC1 241/4885RAB9A 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.